NASDAQ:FGENFibroGen Stock Price, Forecast & News

FibroGen's stock was trading at $35.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FGEN stock has decreased by 7.7% and is now trading at $32.69. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for FibroGen.

FibroGen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for FibroGen.

FibroGen Inc (NASDAQ:FGEN) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.50. The biopharmaceutical company earned $24.40 million during the quarter, compared to analyst estimates of $72.58 million. FibroGen had a negative net margin of 42.75% and a negative return on equity of 19.32%. The business's revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.53) earnings per share. View FibroGen's earnings history.

6 Wall Street analysts have issued 12 month price targets for FibroGen's stock. Their forecasts range from $40.00 to $80.00. On average, they anticipate FibroGen's stock price to reach $57.60 in the next year. This suggests a possible upside of 76.2% from the stock's current price. View analysts' price targets for FibroGen.

Press coverage about FGEN stock has been trending negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. FibroGen earned a coverage optimism score of -2.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutFibroGen.

Some companies that are related to FibroGen include Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Mylan (MYL), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Myokardia (MYOK) and Reata Pharmaceuticals (RETA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.88%), Primecap Management Co. CA (5.64%), Janus Henderson Group PLC (3.46%), State Street Corp (2.99%), JPMorgan Chase & Co. (1.89%) and First Trust Advisors LP (1.48%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View institutional ownership trends for FibroGen.

FGEN stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, JPMorgan Chase & Co., Morgan Stanley, Morgan Stanley, Two Sigma Investments LP, Rafferty Asset Management LLC, Bank of New York Mellon Corp, and Pinnacle Associates Ltd.. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, Elias Kouchakji, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thomas B Neff, and Thomas F Kearns Jr. View insider buying and selling activity for FibroGen.

FGEN stock was acquired by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Janus Henderson Group PLC, BlackRock Inc., Invesco Ltd., Geode Capital Management LLC, Alliancebernstein L.P., Moody Aldrich Partners LLC, and Foresite Capital Management III LLC. View insider buying and selling activity for FibroGen.

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FGEN stock can currently be purchased for approximately $32.69.

FibroGen has a market capitalization of $2.91 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe.

The official website for FibroGen is www.fibrogen.com.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]